[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559319":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":18,"centralContacts":53,"locations":63,"responsibleParty":77,"collaborators":18,"id":79,"slug":18,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":80,"sex":86,"minAge":87,"maxAge":18,"enrollmentInfo":88,"targetDuration":18,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":66,"whyStopped":18,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Vastra Gotaland Region","OTHER_GOV",[8,14,19,24,27,32],{"label":9,"type":10,"description":11,"interventionNames":12},"Bisoprolol","ACTIVE_COMPARATOR","Bisoprolol within 24 hours of PCI",[13],"Drug: Bisoprolol Oral Tablet",{"label":15,"type":16,"description":17,"interventionNames":18},"No Bisoprolol","NO_INTERVENTION","no beta blocker until day 7±12 hours",null,{"label":20,"type":10,"description":21,"interventionNames":22},"Ramipril","Ramipril within 24 hours of PCI",[23],"Drug: Ramipril Oral Product",{"label":25,"type":16,"description":26,"interventionNames":18},"No Ramipril","no ramipril until day 7±12 hours after PCI",{"label":28,"type":10,"description":29,"interventionNames":30},"Dapagliflozin","Dapagliflozin within 24 hours versus",[31],"Drug: Dapagliflozin Oral Product",{"label":33,"type":16,"description":34,"interventionNames":18},"No Dapagliflozin","no dapagliflozin treatment until day 7±12 hours after PCI",[36,43,48],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","Bisoprolol Oral Tablet","Timing of drug intervention after PCI",[9],[42],"Betablocker",{"type":37,"name":44,"description":39,"armGroupLabels":45,"otherNames":46},"Ramipril Oral Product",[20],[47],"ACE inhibitor",{"type":37,"name":49,"description":39,"armGroupLabels":50,"otherNames":51},"Dapagliflozin Oral Product",[28],[52],"SGLT2 inhibitor",[54,59],{"name":55,"role":56,"phone":57,"phoneExt":18,"email":58},"Björn Redfors, Professor","CONTACT","+46 31342100","bjoern.redfors@wlab.gu.se",{"name":60,"role":56,"phone":61,"phoneExt":18,"email":62},"Margareta Scharin Täng, PhD","0736916467","margareta.scharin.tang@vgregion.se",[64],{"facility":65,"status":66,"city":67,"state":18,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":18},"Sahlgrenska University Hospital","RECRUITING","Gothenburg","41345","Sweden","SE",{"type":72,"coordinates":73},"Point",[74,75],11.96679,57.70716,{"lat":75,"lon":74},{"type":78,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100559319",false,"NCT06562582","STunning in Acute Myocardial Infarction - BAS","STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium\u002FGlucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria","STAMI-BAS","Inclusion Criteria:\n\n1. Patients with STEMI who undergo primary PCI within 6 hours of symptom onset (Excluding prodromal symptoms)\n2. Informed consent\n\nExclusion Criteria:\n\n1. Killip class ≥ 3\n2. Chronic kidney disease with GFR \\\u003C 25 ml\u002Fmin\u002F1.73 m2\n3. Pre-existing non-reversible cardiac dysfunction or heart failure\n4. Current treatment with any beta blocker, RAAS inhibitor or SGLT2 inhibitor\n5. Absolute or relative contraindication to any one of the study drugs that confers a risk of patient safety if the patient participates in the trial and adheres to the protocol-specified recommendations, per the assessment of the treating physician\n6. Life expectancy less than one year\n7. Pregnancy or women of childbearing potential who is not sterilized or is not using a medically accepted form of contraception","ALL","18 Years",{"count":89,"type":90},120,"ESTIMATED","INTERVENTIONAL",[93],"PHASE4","The objective of this trial is to examine the effect of immediate versus late administration of beta blockers, angiotensin converting enzyme inhibitors (ACEI), and sodium\u002Fglucose cotransporter 2 (SGLT2) inhibitors on echocardiographic parameters and biomarkers in subjects with ST-elevation myocardial infarction (STEMI)",[96],"Myocardial Infarct",[98,99,9,20,28,100],"ST infarction","PCI","Global longitudinal strain (GLS, %)","2025-06-24",{"date":103,"type":104},"2025-06-27","ACTUAL",{"date":106,"type":104},"2025-01-06",{"date":108,"type":90},"2027-12-31",{"name":5,"class":6},1]